List of Excipients in Branded Drug MIDODRINE HYDROCHLORIDE

Generic Drugs Containing MIDODRINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Impax Generics	midodrine hydrochloride	0115-4211	CELLULOSE, MICROCRYSTALLINE
Impax Generics	midodrine hydrochloride	0115-4211	MAGNESIUM STEARATE
Impax Generics	midodrine hydrochloride	0115-4211	SILICON DIOXIDE
Impax Generics	midodrine hydrochloride	0115-4211	STARCH, CORN
Impax Generics	midodrine hydrochloride	0115-4211	TALC

What are the Most Frequently-Used Excipients in MIDODRINE HYDROCHLORIDE?

# Of NDCs	Excipient
46	CELLULOSE, MICROCRYSTALLINE
19	CROSCARMELLOSE SODIUM
3	CROSPOVIDONE
1	FD&C RED NO. 40 ALUMINUM LAKE
5	FD&C YELLOW NO. 6

Midodrine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Midodrine hydrochloride is a mature, post-exclusivity alpha-1 adrenergic agonist marketed primarily as an immediate-release oral tablet for symptomatic orthostatic hypotension. The strongest commercial opportunity is a reliable, low-cost tablet platform with complete 2.5 mg, 5 mg, and 10 mg strength coverage. Higher-value opportunities include orally disintegrating tablets, unit-dose oral liquids, and formulation improvements that address swallowing difficulty, dose flexibility, and adherence without increasing supine-hypertension risk.

The molecule does not support a conventional biologic or biosimilar strategy. Commercial protection must come from formulation, device, manufacturing, supply-chain, or regulatory differentiation rather than the active ingredient.

What is the FDA status of midodrine hydrochloride?

Midodrine hydrochloride tablets are FDA-approved for the treatment of symptomatic orthostatic hypotension. The reference product, ProAmatine, was approved under NDA 019815. Generic midodrine hydrochloride tablets are marketed in 2.5 mg, 5 mg, and 10 mg strengths through the abbreviated new drug application pathway.[1][2]

Attribute	Midodrine hydrochloride
Active ingredient	Midodrine hydrochloride
Pharmacologic class	Alpha-1 adrenergic agonist
Primary approved use	Symptomatic orthostatic hypotension
Common dosage forms	Immediate-release tablets
Common strengths	2.5 mg, 5 mg, 10 mg
Reference product	ProAmatine
Regulatory pathway for standard generic	ANDA
Exclusivity profile	Mature, post-innovator exclusivity
Biosimilar relevance	None
Principal safety issue	Supine hypertension

Midodrine is converted to desglymidodrine, the active metabolite responsible for most pharmacologic activity. The product label limits late-day dosing because of the risk of supine hypertension. That restriction materially affects the commercial value of extended-release or long-acting formulations.[1]

What excipients are used in midodrine hydrochloride tablets?

There is no single mandatory excipient composition for generic midodrine hydrochloride tablets. FDA-approved labels show that manufacturers use different combinations of fillers, binders, disintegrants, glidants, lubricants, and coating materials.[2]

Common excipient classes include:

Excipient function	Representative options	Strategic purpose
Diluent	Microcrystalline cellulose, lactose, calcium phosphate, mannitol	Tablet mass and compressibility
Binder	Povidone, copovidone, pregelatinized starch	Granule strength and hardness
Disintegrant	Sodium starch glycolate, crospovidone, croscarmellose sodium	Rapid tablet breakup
Glidant	Colloidal silicon dioxide	Powder flow and content uniformity
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection and manufacturing control
Taste modifier	Sucralose, aspartame, acesulfame potassium, flavor systems	Critical for orally disintegrating or liquid products
Coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide	Identification, handling, taste, and light protection
Suspending agent	Xanthan gum, hypromellose, sodium carboxymethylcellulose	Oral-liquid physical stability
Preservative	Product-specific antimicrobial system	Multidose liquid microbiological control

The commercial target should not be to copy a particular brand’s excipient list. The target should be to establish a robust formulation that meets dissolution, content uniformity, stability, manufacturability, and bioequivalence requirements.

How should the excipient system be designed for immediate-release tablets?

A conventional immediate-release formulation has the lowest regulatory and technical risk. The preferred design is a directly compressible or dry-granulated blend that produces rapid disintegration without excessive hardness.

Recommended tablet platform

A practical development platform would use:

• Microcrystalline cellulose or a comparable diluent for compactibility.
• Crospovidone or sodium starch glycolate for rapid disintegration.
• Colloidal silicon dioxide for flow improvement.
• Magnesium stearate or sodium stearyl fumarate at controlled concentration.
• A low-risk binder only if tablet strength or content uniformity requires it.
• A film coat for product identification and handling.

Midodrine hydrochloride is administered at relatively low active loads, especially in the 2.5 mg and 5 mg strengths. Low-dose products create greater content-uniformity risk than 10 mg tablets. Segregation control, ordered mixing, particle-size management, and blend sampling are therefore more important than maximizing drug loading.

The formulation should target prompt release across physiologic pH conditions. Excessive hydrophobic lubricant, overcompression, or high binder levels can slow dissolution. These risks are manageable but should be controlled during design-of-experiments work.

Excipient risks

Lactose can reduce cost but may create concerns for patients with lactose intolerance and can introduce supplier or moisture-control issues. Starch-based systems may improve disintegration but can increase variability if moisture is not controlled. Mannitol is attractive for orally disintegrating products but generally carries a higher cost than conventional tablet fillers.

Magnesium stearate is well established but can retard wetting and dissolution when overmixed. Sodium stearyl fumarate may offer a different lubrication profile but can require process optimization. The best commercial formulation is likely to use standard compendial excipients with multiple qualified suppliers rather than a novel excipient.

What excipients are suitable for midodrine orally disintegrating tablets?

An orally disintegrating tablet could address patients with dysphagia, frailty, neurological disease, or difficulty taking medication during symptomatic episodes. The main formulation issues are taste, mechanical strength, tablet friability, and rapid dispersion.

Preferred ODT excipient strategy

A high-value ODT formulation would typically combine:

• Mannitol for mouthfeel and cooling sensation.
• Microcrystalline cellulose or silicified microcrystalline cellulose for structure.
• Crospovidone or croscarmellose sodium for rapid disintegration.
• A flavor and sweetener system for the bitter or pharmacologically active taste.
• Colloidal silicon dioxide for flow.
• A low-level lubricant compatible with rapid wetting.
• Taste masking through polymer coating, ion exchange, complexation, or multiparticulate coating if sensory testing requires it.

Direct compression offers a comparatively simple manufacturing route. Lyophilized tablets can disintegrate rapidly but have higher manufacturing complexity, fragile handling characteristics, and greater packaging requirements.

A midodrine ODT should not be positioned merely as a convenience product. Its commercial value would depend on demonstrated advantages in administration, adherence, caregiver use, or access during orthostatic episodes. An ODT that disintegrates rapidly but has poor taste or high friability would have limited market value.

Could an oral liquid create a commercial opportunity?

A ready-to-use oral solution or concentrated unit-dose liquid could serve patients who cannot swallow tablets and could support institutional, home-care, and caregiver administration. The principal challenge is not dose delivery. It is stability, palatability, preservative control, and dosing accuracy.

Oral-liquid formulation priorities

The development program should evaluate:

1. Aqueous solubility and pH-dependent stability.
2. Chemical degradation over the intended shelf life.
3. Container-closure compatibility.
4. Light and oxygen sensitivity.
5. Taste masking at the 2.5 mg, 5 mg, and 10 mg dose-equivalent levels.
6. Dosing accuracy with oral syringes.
7. Microbial limits for multidose packaging.
8. Compatibility with enteral feeding tubes if hospital use is targeted.

A unit-dose cup or oral syringe format may provide greater commercial differentiation than a conventional multidose bottle. It can reduce dosing errors and remove the need for preservatives, although unit-dose packaging raises manufacturing and distribution costs.

A liquid product should avoid creating a dosing pattern that increases late-day exposure. The label’s warning regarding supine hypertension remains relevant regardless of dosage form.[1]

Is an extended-release formulation commercially attractive?

An extended-release product has theoretical convenience advantages but carries substantial clinical and regulatory risk. Midodrine’s active metabolite has a relatively short duration of action, while supine hypertension is a central safety concern. Extending exposure into periods when the patient is recumbent could reduce the benefit-risk profile.

An extended-release formulation would require evidence that it:

• Maintains symptom control during clinically relevant upright periods.
• Does not materially increase nighttime or supine blood pressure.
• Preserves practical dose timing.
• Has predictable release across fed and fasted conditions.
• Does not produce dose dumping or excessive metabolite exposure.

The product could require a 505(b)(2) application if the formulation creates a new clinical profile that cannot be supported solely through conventional ANDA bioequivalence. That pathway would increase clinical, regulatory, and commercialization costs.[3]

The more defensible opportunity is a controlled-duration product designed for daytime use, not an unrestricted 24-hour formulation. Even then, the commercial case would depend on clinical evidence rather than formulation novelty alone.

What manufacturing and excipient barriers affect generic midodrine?

The active ingredient is commercially mature, so the principal manufacturing barriers are execution risks:

• Low-dose content uniformity.
• Blend segregation.
• Tablet capping or lamination at high compression force.
• Lubricant overmixing and dissolution slowdown.
• Moisture-related stability.
• Coating defects at small tablet sizes.
• Supply reliability for pharmaceutical-grade excipients.
• Consistent performance across multiple manufacturing sites.

A dual-source excipient strategy is commercially valuable. The formulation should be screened against at least two qualified sources for each critical excipient, particularly microcrystalline cellulose, crospovidone, magnesium stearate, and coating polymers.

For an ODT or liquid, the critical suppliers would shift toward mannitol, sweeteners, flavors, suspending agents, preservatives, and specialized packaging components. Supplier qualification should begin early because sensory and stability performance can vary by grade and source.

What patents and exclusivity protect midodrine hydrochloride?

Midodrine hydrochloride is a post-innovator, generic-market product. The basic active ingredient, conventional tablet, and original approved use are not expected to provide a meaningful current exclusivity barrier. Commercial protection is more likely to arise from:

• A novel ODT architecture.
• A taste-masked particle or coated multiparticulate.
• A stable, preservative-free oral liquid.
• A unit-dose delivery system.
• A specific excipient combination with demonstrated performance.
• A manufacturing process that improves content uniformity or stability.
• A clinically differentiated modified-release profile.

Patent claims should be drafted around measurable technical features rather than broad excipient lists. Stronger claim themes could include disintegration time, dissolution profile, particle coating thickness, taste-masking performance, water activity, preservative-free stability, or a defined impurity profile.

An ANDA applicant should review current Orange Book listings, FDA patent certifications, and Paragraph IV litigation before launch planning. A conventional generic applicant would ordinarily use a Paragraph III or Paragraph IV certification depending on any listed patent status at filing.[4] No biosimilar pathway applies because midodrine hydrochloride is a small-molecule drug.

Which commercial opportunities are most attractive?

Opportunity	Patient or buyer need	Development risk	Commercial potential
Low-cost 2.5/5/10 mg IR tablets	Reliable supply and full strength coverage	Low	Moderate
Scored or flexible-dose tablet	Dose titration and caregiver use	Low to moderate	Moderate
Orally disintegrating tablet	Dysphagia and administration convenience	Moderate	Moderate to high
Preservative-free oral liquid	Pediatric, geriatric, institutional, or enteral use	Moderate	Moderate
Unit-dose oral liquid	Dosing accuracy and portability	Moderate	Moderate
Extended-release tablet	Reduced dosing frequency	High	Uncertain
Novel transdermal or buccal product	Alternative delivery	High	Uncertain

The most attractive near-term strategy is a differentiated immediate-release portfolio: standard tablets for volume, an ODT for adherence and swallowing limitations, and a liquid or unit-dose product for institutional and caregiver channels.

How does midodrine compare with competing orthostatic-hypotension products?

Midodrine competes with pharmacologic and nonpharmacologic treatments for orthostatic hypotension, including fludrocortisone, droxidopa, and compression-based interventions. Its principal competitive advantages are established use, multiple strengths, oral administration, and generic pricing. Its principal limitation is the risk of supine hypertension and the need for daytime dosing.[1][5]

Droxidopa may compete where clinicians seek a different mechanism or a branded treatment option, while fludrocortisone may be selected for volume-expansion strategies. Midodrine’s formulation opportunity is therefore concentrated in administration convenience, dose flexibility, supply reliability, and price.

What revenue exposure and launch risks should investors assess?

Public financial reporting generally does not isolate midodrine hydrochloride revenue by product, formulation, or strength. The market is likely to be price-sensitive, with revenue concentrated among manufacturers that maintain supply, secure pharmacy-channel access, and control manufacturing costs.

Key launch risks include:

• Rapid price erosion after additional generic entry.
• Limited prescriber willingness to switch stable patients.
• Low willingness to pay for convenience absent clinical evidence.
• FDA review questions regarding dosage-form equivalence.
• Taste or stability failure in ODT and liquid products.
• Supine-hypertension concerns limiting adoption of long-acting products.
• Channel concentration among wholesalers and institutional buyers.

A formulation company should model value from market share retention and channel expansion rather than assume branded-drug pricing. An ANDA product with strong supply reliability may outperform a technically novel product with higher manufacturing cost.

Key Takeaways

• Midodrine hydrochloride is a mature generic-market drug with no biosimilar opportunity.
• The lowest-risk commercial product is a robust 2.5 mg, 5 mg, and 10 mg immediate-release tablet portfolio.
• Low-dose content uniformity and dissolution control are central formulation issues.
• ODT products offer the clearest differentiated opportunity, provided taste masking and friability are solved.
• Preservative-free or unit-dose oral liquids could address dysphagia, caregiver, institutional, and enteral-use needs.
• Extended-release development has higher clinical and regulatory risk because of supine hypertension.
• New protection should focus on measurable formulation and manufacturing performance, not generic excipient combinations.
• Orange Book review, Paragraph IV analysis, and current FDA listing verification should precede launch investment.

FAQs

Can midodrine hydrochloride be formulated as an orally disintegrating tablet?

Yes. The principal technical requirements are taste masking, rapid disintegration, adequate mechanical strength, and bioequivalence to the reference immediate-release tablet.

Which excipient is best for a midodrine ODT?

Mannitol is a strong starting diluent because it provides good mouthfeel. Crospovidone, croscarmellose sodium, or sodium starch glycolate can be evaluated as disintegrants, with the final choice determined by dissolution, friability, and sensory results.

Is a midodrine oral solution likely to need preservatives?

A multidose aqueous product may require a preservative system unless the formulation, packaging, and in-use stability support a preservative-free design. Unit-dose packaging can reduce microbiological risk but increases packaging cost.

Would an extended-release midodrine product automatically receive market exclusivity?

No. A novel dosage form may support patent protection or a 505(b)(2) approval, but exclusivity would depend on the specific regulatory designation, patent scope, and FDA approval basis.

What is the strongest patent strategy for a midodrine formulation?

The strongest strategy generally combines claims directed to a specific dosage-form architecture with performance limitations such as dissolution, disintegration, taste masking, stability, or impurity control. Broad claims covering ordinary fillers and lubricants are more vulnerable to design-around and validity challenges.

References

1. U.S. Food and Drug Administration. (2010). ProAmatine (midodrine hydrochloride) tablets prescribing information.
2. U.S. National Library of Medicine. (2024). DailyMed: Midodrine hydrochloride tablet labels.
3. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2).
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
5. Freeman, R., Wieling, W., Axelrod, F. B., Benditt, D. G., Benarroch, E., Biaggioni, I., Cheshire, W. P., Chelimsky, T., Cortelli, P., Gibbons, C. H., Goldstein, D. S., Hainsworth, R., Hilz, M. J., Jacob, G., Kaufmann, H., Jordan, J., Lipsitz, L. A., Levine, B. D., Low, P. A., Mathias, C., Raj, S. R., Robertson, D., Sandroni, P., Schatz, I. J., Schondorff, R., Stewart, J. M., & van Dijk, J. G. (2011). Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clinical Autonomic Research, 21(2), 69-72.